Aardvark Therapeutics Investor Webinar Summary Company Overview - **Company**: Aardvark Therapeutics (NasdaqGS:AARD) - **Focus**: Development of therapies for obesity and related metabolic disorders, particularly through innovative drug combinations and mechanisms targeting hunger and appetite regulation Key Points and Arguments Clinical Programs - **ARD201**: A fixed-dose combination of TAS2R agonist (ARD101) and DPP-4 inhibitor (acetagliptin) aimed at treating metabolic obesity, showing promising preclinical results [3][7] - **WE868**: A newly in-licensed program exploring a novel mechanism for obesity, currently in preclinical studies [3][4] - **ARD101**: Currently in the HERO phase 3 study for hyperphagia associated with Prader-Willi syndrome, with expected pivotal data readout in Q3 2026 [5][8] Data Highlights - **ARD201** demonstrated a 19% weight loss in a diet-induced obesity mouse model over 30 days, comparable to high-dose tirzepatide (20.5% weight loss) [10] - **Weight Maintenance**: ARD201 showed preservation of weight loss after discontinuation of GLP-1 therapies, achieving approximately 30% weight loss when combined with a microdose of tirzepatide [11] - **Body Composition**: ARD201 preserved lean mass while reducing fat mass, addressing concerns of lean mass loss associated with GLP-1 therapies [12] - **Glucose Homeostasis**: Improvements in glucose tolerance were observed in mice treated with ARD201, indicating potential benefits for patients with obesity-related diabetes [13] Mechanism of Action - **Gut-Brain Signaling**: ARD101 targets gut peptide hormone release to regulate hunger, contrasting with GLP-1 therapies that primarily focus on appetite signaling [6] - **WE868 Mechanism**: Modulates cellular energy use without mitochondrial uncoupling, leading to increased energy expenditure and weight loss [16] Industry Context - **Obesity Treatment Landscape**: The prevalence of obesity is rising, necessitating effective treatments. Aardvark's approach aims to mimic the effects of bariatric surgery through pharmacotherapy [35][38] - **Emerging Trends**: The development of combination therapies and multi-agonist approaches is seen as a future direction in obesity treatment, with potential for improved efficacy and reduced side effects [44][48] Challenges and Unmet Needs - **Side Effects**: Current GLP-1 therapies are associated with nausea and lean mass loss, highlighting the need for better-tolerated options [47][50] - **Insurance Coverage**: Changes in insurance coverage for GLP-1 therapies in Massachusetts may limit access for patients, emphasizing the need for alternative treatments [56] Additional Insights - **Gut-Brain Axis Research**: Ongoing studies into the gut-brain axis and its role in regulating appetite and glucose homeostasis are critical for understanding obesity mechanisms [21][27] - **Nutrient Sensing**: The interplay between nutrient sensing and gut hormones is crucial for developing effective obesity treatments [33][34] Conclusion Aardvark Therapeutics is positioned to make significant contributions to the obesity treatment landscape through innovative drug development and a focus on understanding the underlying mechanisms of hunger and appetite regulation. The upcoming clinical milestones and ongoing research into new compounds like WE868 could provide valuable insights and therapeutic options for patients struggling with obesity and related metabolic disorders.

Core Viewpoint - Novo Nordisk has lowered its growth expectations for its key obesity and diabetes treatment drugs due to prescription trends, competition, and pricing pressures [1] Financial Performance - The company's quarterly net profit was 20 billion Danish kroner (approximately 3.1 billion USD), aligning with analyst expectations of 20.12 billion Danish kroner [1] Market Dynamics - The treatments Wegovy and Ozempic have become critical growth drivers for the company, but recent disappointing trial results and increasing competition in the obesity drug market have raised concerns [1] - Challenges also stem from U.S. drug pricing and tariff policies, which are impacting the company's outlook [1] Leadership and Strategic Challenges - Novo Nordisk is facing leadership changes and opposition to a key acquisition, contributing to the uncertainty surrounding the company [1] Analyst Sentiment - Analysts have mixed views on the stock; Jefferies recently downgraded it to underperform, while Berenberg maintains a positive outlook, suggesting that the company has reached a "peak of uncertainty" [1]

Core Insights - The article discusses the potential of multi-receptor agonists, specifically LY3437943, in improving health outcomes for patients with type 2 diabetes and obesity, showing promising results in both short-term and long-term health improvements [5][10]. Group 1: Study Overview - A randomized, double-blind, placebo-controlled phase 1b trial was conducted from December 2019 to December 2020 across four research centers in the U.S., involving 72 adult patients with type 2 diabetes [6]. - Patients were randomly assigned to receive different doses of LY3437943, a placebo, or a control group receiving 1.5 mg of Dulaglutide, with treatment lasting 12 weeks [6]. Group 2: Safety and Efficacy Results - The primary focus was on the safety and tolerability of LY3437943, while secondary endpoints assessed pharmacodynamics and pharmacokinetics [7]. - Adverse events related to treatment were reported in 63% of the LY3437943 group, 60% in the Dulaglutide group, and 54% in the placebo group, with gastrointestinal symptoms being the most common adverse reactions [7]. Group 3: Pharmacokinetics and Outcomes - Pharmacokinetic analysis indicated a proportional relationship between LY3437943's pharmacological parameters and dosage, with a half-life of approximately 6 days [8]. - After 12 weeks, average daily blood glucose levels significantly decreased in the high-dose groups compared to baseline, with reductions of 2.8 mmol/L, 3.1 mmol/L, and 2.9 mmol/L for the respective high-dose groups [8]. - Hemoglobin A1c levels also improved significantly in the high-dose groups, with reductions of 1.4%, 1.6%, and 1.2% [10]. - Weight loss was dose-dependent, with the highest dose group achieving an average weight reduction of 8.96 kg [10]. Group 4: Conclusion and Future Research - Overall, LY3437943 demonstrated safety profiles comparable to existing incretin-based therapies while significantly improving blood glucose control and weight status over the 12-week treatment period [10]. - These findings lay a solid foundation for further phase 2 clinical studies in the treatment of type 2 diabetes and obesity [10].

Core Viewpoint - Novo Nordisk is attempting to acquire Metsera for at least $6.5 billion to strengthen its position in the obesity treatment market, competing against Pfizer's existing agreement with Metsera [1][4]. Group 1: Acquisition Details - Novo Nordisk has proposed a cash offer of $56.50 per share for Metsera, with potential milestone payments increasing the total offer to a maximum of $77.75 per share, surpassing Pfizer's highest bid of $70 per share by 11% [2][4]. - Metsera has indicated that Novo Nordisk's new offer is superior to Pfizer's, allowing them to terminate the agreement with Pfizer if they find Novo Nordisk's proposal more favorable [1][4]. - The cash payment will be made upon signing the agreement in exchange for 50% of Metsera's equity in non-voting preferred shares, with milestone payments issued upon completion of the transaction for the remaining shares [3]. Group 2: Market Context - The obesity treatment market is projected to reach $100 billion by 2030, prompting major pharmaceutical companies to acquire smaller firms with promising drug candidates [4]. - Metsera is developing several experimental weight loss drugs, including a long-acting insulin analog that may offer a more favorable dosing schedule compared to existing market leaders from Novo Nordisk and Eli Lilly [4]. Group 3: Company Strategy and Challenges - Novo Nordisk is undergoing a transformation to regain its leading position in the obesity treatment sector, having previously seen its stock price surge due to the weight loss drug boom [5]. - The company has recently experienced significant management changes, including the resignation of over half of its board members, as it seeks to establish a performance culture to reclaim market share in the U.S. [6]. - Novo Nordisk faces pressure from former President Donald Trump's initiatives to lower drug prices, which could impact its revenue from key products like Ozempic [6].

Core Viewpoint - The company announced plans to present multiple obesity drug candidates, including ASC30 and the ASC31 and ASC47 combination therapy, at the 2025 ObesityWeek® in Atlanta, Georgia [1] Group 1 - The presentation will be in the form of a poster at the ObesityWeek® event [1] - The founder and CEO, Dr. Wu Jinzi, expressed excitement about the ongoing progress of their small molecule and peptide obesity pipeline [1] - The advancements reflect the company's commitment to developing highly differentiated obesity treatment solutions [1]

Core Insights - The company announced that it will present multiple obesity drug candidates, including ASC30 and the combination therapy of ASC31 and ASC47, at the 2025 ObesityWeek in Atlanta, Georgia [1] - The CEO expressed excitement about the progress of their small molecule and peptide obesity pipeline, highlighting the company's commitment to developing differentiated obesity treatment options [1] Company Developments - The company is actively advancing its obesity treatment pipeline, showcasing its candidates at a significant industry event [1] - The announcement reflects the company's strategic focus on addressing obesity through innovative therapies [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced its participation in the 2025 Obesity Week in Atlanta, Georgia, where it will present multiple obesity treatment candidates, including ASC30, ASC31, and ASC47 combination therapy [1] Group 1: Presentation Details - The company will report on the oral GLP-1 receptor biased small molecule agonist ASC30 in a 28-day multiple ascending dose study [1] - An Ib phase study on ASC30, a monthly subcutaneous injection small molecule GLP-1 receptor agonist in obese subjects, will also be presented [1] - The combination of GLP-1 receptor/GLP receptor agonist peptides ASC31 and ASC47 showed a relative weight loss improvement of 119.6% compared to tirzepatide in diet-induced obese mice [1] Group 2: Company Statements - The founder, chairman, and CEO of the company expressed excitement about the ongoing progress of their small molecule and peptide obesity pipeline, highlighting a strong commitment to developing differentiated obesity treatment solutions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 Ascletis Pharma Inc. 歌禮製藥有限公司 歌禮將攜ASC30口服片、ASC30注射劑和ASC31與ASC47聯合療法的 研究結果亮相2025年肥胖周（ObesityWeek®） 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈將在美國佐治亞州亞特蘭大舉行的2025 年肥胖周（ObesityWeek®）以壁報形式報告多款肥胖症候選藥物，包括ASC30以及 ASC31與ASC47聯合療法。 報告細節： ASC30是一款正在臨床研究中的小分子GLP-1R偏向激動劑，具有獨特和差異化性 質，使得同一小分子同時適用於口服片劑和皮下注射給藥成為可能。ASC30是一 種新化學實體(NCE)，擁有 ...

Core Viewpoint - The completion of subject enrollment in the Phase IIa study of ASC30, a small molecule GLP-1 receptor agonist for obesity treatment, marks a significant milestone in the development of this innovative therapy [1][2]. Group 1: Study Details - The Phase IIa study is a 12-week, randomized, double-blind, placebo-controlled, multi-center clinical trial conducted in the U.S. with 65 participants, all of whom are either obese or overweight with at least one weight-related comorbidity [1]. - The study aims to evaluate the safety, tolerability, and efficacy of ASC30 in subjects with a body mass index (BMI) of ≥ 30 kg/m² or those with a BMI between 27 kg/m² and 30 kg/m² [1]. - Top-line data from the study is expected in the first quarter of 2026 [1]. Group 2: Pharmacokinetics and Technology - The observed half-life of ASC30 in obese subjects is 46 days, supporting a once-monthly dosing regimen, while the terminal half-life is 36 days [1]. - The peak-to-trough ratio of the drug is approximately 1.5:1, indicating favorable pharmacokinetic properties [2]. - ASC30 is developed using the company's proprietary ultra-long-acting drug development platform (ULAP), which overcomes limitations of albumin-dependent half-life extension technologies [2]. Group 3: Product Characteristics - ASC30 is the first and only small molecule GLP-1 receptor agonist that can be administered both orally and via subcutaneous injection, suitable for both weight loss treatment and maintenance [2][3]. - The compound is a new chemical entity (NCE) with patent protection in the U.S. and globally until 2044, excluding any patent extensions [3].

Core Insights - The company, 来凯医药-B (02105), announced positive preliminary results from the Phase I Multiple Ascending Dose (MAD) study of LAE102 for obesity treatment in China [1][2] - The MAD study demonstrated safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE102 in overweight/obese subjects [1] Group 1: Study Results - The MAD study included overweight/obese subjects with an average BMI of 29.4 kg/m² and involved three dosing groups (2 mg/kg, 4 mg/kg, and 6 mg/kg) administered weekly for four weeks [1] - In the 6 mg/kg dosing group, subjects showed an average lean body mass increase of 1.7% and a fat mass reduction of 2.2% by week 5 [1] - After adjusting for the placebo group, the average lean body mass increase reached 4.6%, while fat mass decreased by 3.6% [1] Group 2: Safety and Tolerability - The MAD study confirmed good tolerability and safety, with no serious adverse events reported [1] - Most adverse events during treatment were mild (Grade 1) laboratory abnormalities, with no cases of diarrhea, muscle cramps, or acne reported [1] - Safety results were consistent with previous findings from the single ascending dose (SAD) study, with no new safety signals observed [1] Group 3: Future Development and Partnerships - The positive results from the MAD study support the continued clinical development of LAE102 for obesity treatment [2] - The company is actively negotiating with potential partners who have serious commitments and financial strength to prioritize this project, aiming to accelerate clinical development and commercialization [2] - The company maintains a robust financial position, allowing for selective evaluation of potential partnership structures to maximize global asset potential [2]